Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp)4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo

Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy

(2012) Denise de Oliveira Silva   Anti-Cancer Agents in Medicinal Chemistry

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

(2012) Christian G. Hartinger et al.   ORGANOMETALLICS

Approaching tumour therapy beyond platinum drugs

(2011) A. Bergamo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation

(2011) Marcus Niewald et al.   Radiation Oncology

Inhibition of C6 rat glioma proliferation by [Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential

(2010) Marcel Benadiba et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Organometallic Anticancer Compounds

(2010) Gilles Gasser et al.   JOURNAL OF MEDICINAL CHEMISTRY

Organometallic ruthenium-based antitumor compounds with novel modes of action

(2010) Wee Han Ang et al.   JOURNAL OF ORGANOMETALLIC CHEMISTRY

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

(2009) Frederike Lentz et al.   ANTI-CANCER DRUGS

Areneruthenium complexes as anticancer agents

(2009) Georg Süss-Fink   DALTON TRANSACTIONS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Translating biological insights into clinical endpoints in neuro-oncology

(2009) Markus Bredel   LANCET ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression

(2009) Juliano Miyake et al.   Lipids in Health and Disease

Recent developments in ruthenium anticancer drugs

(2009) Aviva Levina et al.   Metallomics

p53 Mutant Human Glioma Cells Are Sensitive to UV-C-Induced Apoptosis Due to Impaired Cyclobutane Pyrimidine Dimer Removal

(2009) L. F.Z. Batista et al.   MOLECULAR CANCER RESEARCH

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

(2008) C. J. Wheeler et al.   CANCER RESEARCH

Diruthenium(II,III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation

(2008) Geise Ribeiro et al.   POLYHEDRON

Antitumour metal compounds: more than theme and variations

(2007) Michael A. Jakupec et al.   DALTON TRANSACTIONS